Last update 06 Dec 2024

Encaleret sulfate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Encaleret, Encaleret sulfate (USAN), CLTX-305
+ [2]
Target
Mechanism
CaSR antagonists(Calcium sensing receptor antagonists)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Orphan Drug (EU), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC58H70Cl2F2N2O13S
InChIKeyNOJBHZIZNPMQRT-CBASKZFISA-N
CAS Registry1214922-52-7

External Link

KEGGWikiATCDrug Bank
D10116---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hypercalciuric Hypocalcemia, FamilialPhase 3
US
06 Jan 2023
Hypercalciuric Hypocalcemia, FamilialPhase 3
JP
06 Jan 2023
Hypercalciuric Hypocalcemia, FamilialPhase 3
AU
06 Jan 2023
Hypercalciuric Hypocalcemia, FamilialPhase 3
CA
06 Jan 2023
Hypercalciuric Hypocalcemia, FamilialPhase 3
CZ
06 Jan 2023
Hypercalciuric Hypocalcemia, FamilialPhase 3
DK
06 Jan 2023
Hypercalciuric Hypocalcemia, FamilialPhase 3
FR
06 Jan 2023
Hypercalciuric Hypocalcemia, FamilialPhase 3
IT
06 Jan 2023
Hypercalciuric Hypocalcemia, FamilialPhase 3
NL
06 Jan 2023
Hypercalciuric Hypocalcemia, FamilialPhase 3
TW
06 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
13
(Period 1: Encaleret)
vgezyzexri(ceeyfuagsv) = jzongldrhq lzaatfjzdm (gikfbmkdyu, rjhwfodpof - efeyteelxb)
-
19 Nov 2024
(Periods 2 and 3: Encaleret)
vgezyzexri(ceeyfuagsv) = oqshlwplpt lzaatfjzdm (gikfbmkdyu, xeocxpwepy - bckiefwuzc)
Phase 2
13
sncllzzfga(lxbffujwzs) = fwxqkemvuc rtlurofxqr (rruttgacgx )
Positive
12 Oct 2023
Not Applicable
-
ostvbusvlc(qzkizddssc) = dvoranubqa omcnlzyhkc (afrjbsuaor )
-
04 Nov 2022
Phase 2
526
Placebo to MK-5442+Calcium carbonate+Vitamin D3
(Placebo)
ctclamuonu(suxilxsjss) = rwgqweoihx xtskvxmlij (fjismuqjer, pwbudvxjiy - jffycmfloc)
-
16 Nov 2012
Placebo to Alendronate+MK-5442+Calcium carbonate+Vitamin D3
(MK-5442 5 mg)
ctclamuonu(suxilxsjss) = dhwtydsjoi xtskvxmlij (fjismuqjer, pgadlteinf - nbpjrxfdug)
Phase 2
383
Placebo+MK-5442
(MK-5442 2.5 mg)
xgpmqqecij(jmypfdysdl) = kmwvznczlc ruhyhzftul (wqvxsvlghy, kimbejtyji - xyipttabvt)
-
10 Oct 2012
Placebo+MK-5442
(MK-5442 5 mg)
xgpmqqecij(jmypfdysdl) = skeyioyjbk ruhyhzftul (wqvxsvlghy, egcvtpuiza - efeghzfsgh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free